Ibex Investors LLC purchased a new stake in West Pharmaceutical Services Inc. (NYSE:WST) during the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 1,676 shares of the medical instruments supplier’s stock, valued at approximately $207,000.
Several other institutional investors have also made changes to their positions in the company. Riverhead Capital Management LLC lifted its stake in shares of West Pharmaceutical Services by 23.0% in the 3rd quarter. Riverhead Capital Management LLC now owns 4,805 shares of the medical instruments supplier’s stock valued at $593,000 after purchasing an additional 900 shares during the last quarter. Loomis Sayles & Co. L P lifted its stake in West Pharmaceutical Services by 1.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 62,140 shares of the medical instruments supplier’s stock worth $7,673,000 after acquiring an additional 794 shares in the last quarter. Kornitzer Capital Management Inc. KS acquired a new position in West Pharmaceutical Services during the 3rd quarter worth about $27,412,000. Tower Research Capital LLC TRC lifted its stake in West Pharmaceutical Services by 453.0% during the 3rd quarter. Tower Research Capital LLC TRC now owns 6,105 shares of the medical instruments supplier’s stock worth $754,000 after acquiring an additional 5,001 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its stake in West Pharmaceutical Services by 9.1% during the 3rd quarter. Hsbc Holdings PLC now owns 10,406 shares of the medical instruments supplier’s stock worth $1,285,000 after acquiring an additional 867 shares in the last quarter. 92.50% of the stock is currently owned by institutional investors and hedge funds.
WST opened at $106.02 on Friday. West Pharmaceutical Services Inc. has a 12-month low of $82.74 and a 12-month high of $125.09. The company has a current ratio of 2.94, a quick ratio of 2.23 and a debt-to-equity ratio of 0.15. The stock has a market cap of $8.09 billion, a P/E ratio of 38.14, a PEG ratio of 4.09 and a beta of 1.19.
West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, October 25th. The medical instruments supplier reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.70 by $0.06. West Pharmaceutical Services had a return on equity of 15.78% and a net margin of 9.06%. The firm had revenue of $431.70 million for the quarter, compared to analyst estimates of $427.55 million. Equities analysts forecast that West Pharmaceutical Services Inc. will post 2.83 earnings per share for the current year.
WST has been the topic of several research reports. Zacks Investment Research lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Friday, August 10th. ValuEngine raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Wednesday, October 17th.
COPYRIGHT VIOLATION NOTICE: This report was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.thelincolnianonline.com/2018/12/08/ibex-investors-llc-purchases-shares-of-1676-west-pharmaceutical-services-inc-wst.html.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Read More: Day Trading
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.